Q32 Bio Inc. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Q32 Bio Inc. (Ticker: QTTB)
Reporting Period: Fiscal year ended December 31, 2025
Business Model: Clinical-stage biotechnology company focused on developing novel biologics for autoimmune and inflammatory diseases.
Key Asset: Bempikibart (ADX-914), a fully human anti-IL-7Rα antagonist monoclonal antibody for alopecia areata (AA). The company received FDA Fast Track Designation for bempikibart in April 2025.
Strategic Shift: In November 2025, the company sold its ADX-097 asset to Akebia Therapeutics to focus resources on bempikibart.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Collaboration Arrangement Revenue | $53,737 | $0 |
| Total Operating Expenses | $36,835 | $66,102 |
| Net Income (Loss) | $29,821 | $(47,733) |
| Cash and Cash Equivalents (Year End) | $48,297 | $77,965 |
| Net Cash Used in Operating Activities | $(33,543) | $(67,715) |
| Accumulated Deficit | $(204,993) | $(234,814) |
Note: 2025 Net Income is primarily driven by non-cash revenue recognition from the settlement of a prior collaboration liability and a gain on asset sale.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $53.7 million in collaboration revenue in 2025 due to the "Amgen Amendment," which settled a $55.0 million refund liability from a terminated Horizon Therapeutics agreement via an equity grant. This reversed the prior year's loss position.
- Operating Expenses: Total operating expenses decreased by $29.3 million (44%) to $36.8 million. Research and Development (R&D) expenses dropped $29.0 million, largely due to the discontinuation of the ADX-097 program and reduced clinical costs for bempikibart.
- Asset Sale: The company recorded an $11.7 million gain on the sale of the ADX-097 asset to Akebia Therapeutics in November 2025.
- Cash Position: Cash and cash equivalents decreased by approximately $29.7 million, reflecting operating cash burn partially offset by the $7.0 million upfront payment from the ADX-097 sale.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Bempikibart (AA): Enrollment for the SIGNAL-AA Part B Phase 2a trial (33 patients) was completed in October 2025. Topline data is expected in mid-2026.
- Liquidity: Management projects that existing cash ($48.3M), combined with proceeds from a February 2026 registered direct offering and guaranteed milestones from the ADX-097 sale, will fund operations into the fourth quarter of 2027.
Key Risks and Contingencies:
- Capital Requirements: The company has no approved products and expects to incur significant losses until commercialization. Additional capital will be required to complete development.
- Clinical Uncertainty: Success is heavily dependent on bempikibart. While Phase 2a Part A showed hair regrowth, the primary endpoint was not met in the atopic dermatitis (AD) trial Part B.
- Intellectual Property: Rights to bempikibart are licensed from Bristol-Myers Squibb (BMS), requiring milestone payments and royalties upon commercialization.
- Regulatory: The company faces standard biotech risks regarding FDA approval timelines and potential changes in healthcare policy (e.g., Inflation Reduction Act impacts).
Investor Verification Checklist
- Cash Runway: Verify the closing and proceeds of the February 2026 registered direct offering to confirm the Q4 2027 liquidity projection.
- ADX-097 Milestones: Monitor the receipt of the $3.0 million payment due in May 2026 and the $2.0 million near-term milestone from Akebia.
- Bempikibart Data: Await the mid-2026 topline data from the SIGNAL-AA Part B trial to assess the probability of advancing to pivotal trials.
- Amgen Settlement: Confirm that the equity grant to Amgen (Horizon) fully extinguished the $75.1 million contingent milestone liability as reported.
- BMS Obligations: Review the BMS license agreement terms regarding future milestone payments and royalty rates should bempikibart achieve approval.